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Abstract We investigated the association of the angio-
tensin converting enzyme gene (ACE) insertion/deletion 
(I/D) polymorphism, alone or in combination with the 
a-actinin-3 gene (ACTN3) R577X polymorphism, with 
jumping (vertical squat and counter-movement jump tests) 
and sprint ability (30 m dash) in non-athletic, healthy 
young adults [N — 281 (214 male), mean (SD) age 21 
(2) years]. We did not observe any effect of the ACE I/D 
polymorphism on study phenotypes. We repeated the 
analyses separately in men and women and the results did 
not materially change. Likewise, the mean estimates of the 
study phenotypes were similar in subjects with the geno-
type combinations ACE II + ID and ACTN3 XX or ACE 
DD and ACTN3 RR + RX. We found no association 
between the ACE DD and ACTN3 RR + RX genotype 
combination and performance (>90th of the sex-specific 
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percentile). In summary, though the ACE I/D polymor-
phism is a strong candidate to modulate some exercise-
related phenotypes or athletic performance status, this 
polymorphism, alone or in combination with the ACTN3 
R577X polymorphism, does not seem to exert a major 
influence in the muscle 'explosive' power of young healthy 
adults, as assessed during multi-joint exercise tests. 
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Introduction 
One genetic variation that is a candidate to explain indi-
vidual variability in exercise-related phenotypes, and par-
ticularly in muscle phenotypes is the 287 bp insertion/ 
deletion (I/D) polymorphism of the angiotensin converting 
enzyme (ACE) gene. Besides regulating blood pressure, the 
ACE is expressed in skeletal muscle, where it may influ-
ence its function and biomechanical properties (Gordon 
et al. 2001; Jones et al. 2002; Wagner et al. 2006), e.g. its 
product, angiotensin II, acts as a muscle growth factor 
(Jones et al. 2002) that is necessary to induce overload-
induced skeletal muscle hypertrophy (Gordon et al. 2001). 
The ACE D allele is associated with higher ACE activity 
and thus increased angiotensin II levels (Jones et al. 2002); 
thus, this allele would theoretically favour performance in 
power or strength-oriented versus more endurance exercise 
tasks. Indeed, the D allele has been associated with elite 
"sprint" athletic performance (Myerson et al. 1999; Woods 
et al. 2001) and power-related phenotypes in non-athletic 
populations, e.g. preserved quadriceps muscle strength in 
chronic patients (Hopkinson et al. 2004), lower risk of 
skeletal muscle damage induced by eccentric contractions 
(Yamin et al. 2007), or greater gains in knee extensor 
strength after training in old (>60 years) individuals 
(Giaccaglia et al. 2008). 
Another strong candidate to influence muscle pheno-
types is the ACTN3 gene, which encodes for the synthesis 
of a-actinin-3 in skeletal-muscle fibres, a protein necessary 
for producing fast, powerful contractions (Yang et al. 
2003). A premature stop codon polymorphism (R577X) in 
ACTN3 was first described by North et al. (1999). Though 
this genetic variation is not associated with any known 
disease phenotype, the a-actinin-3-deficient XX genotype 
is believed to preclude top-level athletic performance in 
'pure' power and sprint sports (e.g. sprinting and jumping 
events), especially in women (Yang et al. 2003). More 
discrepancy exists on the putative role of the ACTN3 
R577X polymorphism on muscle power phenotypes in 
non-athletic populations, with some authors reporting an 
unfavourable effect of the XX genotype (Vincent et al. 
2007), at least in women (Walsh et al. 2008), and others 
reporting no effect (McCauley et al. 2009). Additional 
controversy stems from the fact that in older adults (mean 
age ~ 65 years), the XX genotype was associated with 
higher knee extensor concentric peak power compared with 
RR and RX genotypes (Delmonico et al. 2007), while 
others found no genotype:phenotype association (San Juan 
et al. 2006). We recently reported no association between 
leg explosive muscle power (jump and sprint tests) and the 
ACTN3 R577X polymorphism in non-athletic young adults 
(Santiago et al. 2009). It was concluded that muscle phe-
notype traits (e.g. power) are complex and thus not likely 
reducible to a single polymorphism such as ACTN3 
R577X. For instance, it could be that ACE I/D and ACTN3 
R577X polymorphisms act in combination to exert their 
influence in exercise-related phenotypes. 
It was the main purpose of our study to examine the 
influence of the ACE I/D polymorphism, alone or in 
combination with the ACTN3 R577X polymorphisms, in 
the muscle power phenotypes of non-athletic adults. We 
hypothesized that, though the more 'endurance-oriented' 
ACTN3 XX genotype is not associated with lower muscle 
explosive power (in jump and sprint tests) as we previously 
showed (Santiago et al. 2009), the combination of the 
ACTN3 R577X and ACE ID polymorphisms may partly 
explain the individual variability in muscle strength phe-
notypes among young adults. 
Methods 
Subjects 
Written consent was obtained from each subject. The study 
protocol was approved by the institutional ethics 
committee [Universidad Europea de Madrid (UEM), 
Spain] and was in accordance with the Declaration of 
Helsinki for Human Research. The study sample comprised 
281 healthy young adults (University students) [mean (SD) 
age 21 (2) years (range 21, 32)] of both genders (214 men, 
67 women) who took part in a previous study on ACTN3 
R577X polymorphism (Santiago et al. 2009). Inclusion 
criteria were to be free of any diagnosed cardiorespiratory 
disease, and not to be engaged in competitive sports such 
as (a) formal, supervised 'power' (e.g. weight lifting or 
alpine skiing) or jumping oriented type of training (e.g. 
plyometrics, volleyball or basketball) or (b) endurance 
training (e.g. running, swimming of bicycling), i.e., per-
forming less than one (power) or three (endurance) struc-
tured weekly training sessions within the last year. All 
participants were of the same Spanish (Caucasian) ancestry 
for at least three generations. 
Genotype assessment 
Our study was designed and performed in accordance with 
the recommendations for the human genotype-phenotype 
association studies recently published by the NCI-NHGRI 
Working Group on Replication in Association Studies 
(Chanock et al. 2007). These recommendations include 
among others, the following items: indicating time period 
and location of subject recruitment, success rate for DNA 
acquisition, sample tracking methods or genotyping with a 
second technology in a second laboratory. 
During winter-spring 2008, we extracted genomic DNA 
from saliva samples of the subjects in two different uni-
versities of the same city (Madrid, Spain): Universidad 
Politécnica and UEM (N — 200 and 84 subjects, respec-
tively). Genotyping of the ACTN3 R577X polymorphism 
was performed during fall 2008 in the genetics laboratory 
of the UEM and the results have been previously published 
(Santiago et al. 2009). The ACE I/D genotyping was per-
formed during spring 2010 in the same laboratory. 
We followed the ACE I/D (rsl799752) and ACTN3 
R577X (rs 1815739) genotyping methods that have been 
applied in previous studies (Gomez-Gallego et al. 2009; 
Santiago et al. 2009). Sequences corresponding to each 
polymorphism were amplified by the polymerase chain 
reaction (PCR) and the resulting PCR products were gen-
otyped using electrophoresis through agarose gel (ACE) or 
restriction fragment length polymorphisms (ACTN3). 
Primers used for the ACE I/D polymorphism were: 5'-TG 
GAGACCACTCCCATCCTTTCT and 5'-GATGTGGCC 
ATCACATTCGTCAGAT. The PCR conditions were as 
follows: initial denaturing at 95°C 5 min; 35 cycles at 95°C 
30 s, 58°C 30 s, 72°C 1 min and a final extension at 72°C 
5 min. The ACE I/D fragments without insertion (D allele) 
and with insertion (I allele) of 190 and 490 bp, 
respectively, were detected on a 1.5% agarose gel con-
taining ethidium bromide. In order to avoid a misclassifi-
cation of ID heterozygotes as DD homozygotes, a second 
PCR reaction was performed in all of the samples initially 
classified as DD with the following insertion-specific pri-
mer pairs (Lindpaintner et al. 1995): 5'-TGGGACCACA 
GCGCCCGCCACTAC and 5'-TCGCCAGCCCTCCCAT 
GCCCATAA. The PCR conditions were similar as 
described above, except for the annealing temperature 
(64°C). Only the allele I produces a 335 bp amplicon, 
identified on an a 1.5% agarose gel stained with ethidium 
bromide. Figure 1 shows a representative example of 
visual detection of ACE genotypes. 
For the ACTN3 R577X polymorphism, a fragment of 
291 bp was amplified with the following primers: ACTN3-
F 5'-CTGTTGCCTGTGGTAAGTGGG labelled a 5' with 
Fig. 1 Example of visual detection of ACE genotypes, a (Upper 
figure) Representative gel of angiotensin converting enzyme gene 
(ACE) genotyping. Lane 1 Homozygous DD individual (190 bp), lane 
2 homozygous II individual (480 bp), lane 3 heterozygous ID 
individual (190 and 480 bp), lane 4 negative control, lane 5 Ladder 
100 bp (Biotools, Spain), b (Lower figure) Representative gel of 
internal ACE genotyping. Lane 1 Positive internal ACE PCR 
(335 bp), lane 2 negative internal ACE PCing enzyme R, lane 3 
Ladder 100 bp (Biotools, Spain) 
VIC and ACTN3-R 5'-TGGTCACAGTATGCAGGAG 
GG. The PCR conditions were as follows: initial denatur-
ing at 95°C 5 min; 35 cycles at 95°C 30 s, 60°C 30 s, 72°C 
30 s and a final extension at 72°C 10 min. ACTN3 geno-
types were established by enzymatic digestion of ampli-
cons with Dde I. The R577X change creates a restriction 
site resulting in fragments of 108, 97 and 86 bp. Digestion 
of the R577 allele results in fragments of 205 and 86 bp, 
and digestion of the 577X allele results in fragments of 
108, 97 and 86 bp. The digestion products detected by 
capillary electrophoresis (ABI Prism 310 genetic analyzer; 
Applied Biosystems, Foster City, CA) were those labelled 
with VIC, i.e. 108 bp for 577X, and 205 bp for R577. 
Following recent recommendations (Chanock et al. 
2007), genotype results of both ACE I/D and ACTN3 
R577X polymorphisms were replicated in 100 samples in a 
different laboratory (Progenika Biopharma, Parque Tec-
nológico de Zamudio, Derio-Vizcaya, Spain) using a dif-
ferent technology, i.e. newly developed low-density DNA 
microarray based on allele-specific probes. The design, 
fabrication, validation and analysis of the arrays were 
performed following the procedure described elsewhere 
(Tejedor et al. 2005). In brief, the PCR products were 
fluorescently labelled and hybridized to the DNA micro-
array in an automated platform (Ventana Medical Systems, 
Inc., Tucson, AZ, USA). The microarrays were scanned 
(Innopsys S.A., Carbonne, France) and we determined 
variants using a developed software that converts the 
intensity of the spots into the genotype of each variant. 
No failures occurred in sample collection and DNA 
acquisition. Genotyping success rate was >98.9% (three 
missing data for ACE I/D and only one missing data for 
ACTN3 R577X). Parallel genotyping results of the two 
polymorphisms showed 100% concordance between the 
two laboratories (UEM and Progenika). 
Phenotype assessment 
Assessment of leg muscle 'explosive' power was per-
formed during spring 2008 in the same location (UEM) and 
all the tests were supervised by the same researchers, as 
detailed elsewhere (Santiago et al. 2009). Squat (SJ) and 
counter-movement jump (CMJ) tests were performed using 
an infrared contact timing platform (Globus Ergo Tester, 
Codogné, Italy) to evaluate leg muscles' ability to produce 
'explosive' power (Young et al. 2001). Both tests were 
performed three times (each separated by a 2-min rest 
period) and the best score was retained. 
Subjects also performed a 30 m sprint test in an indoor 
rubberized track under two conditions: (1) starting from 
the stationary (standing) position (Young et al. 2001) and 
(2) starting with a previous 15 m run thereby allowing 
achieving higher speeds in the first meters of the test 
(Alcaraz et al. 2009). The difference in performance time 
between both tests (at 15 and 30 m, respectively) was used 
as an index of subject's ability to produce acceleration, i.e. 
lesser difference implies higher acceleration capacity. We 
used photoelectric gates at 0, 15 and 30 m to start and stop 
a digital timer. We previously showed the reliability of the 
aforementioned tests for explosive leg muscle power 
assessment with a subgroup of the present subjects 
(Santiago et al. 2009). 
Statistical analysis 
Hardy-Weinberg equilibrium was tested using a % test. 
We compared the genotype frequencies between males and 
females with the % test. 
We analysed the differences in the study phenotypes 
among variants of the ACE I/D polymorphism by one-way 
analysis of covariance (ANCOVA), where the polymor-
phism was entered as a fixed factor, the phenotype was 
entered as a dependent variable, and age, weight and height 
were entered as covariates. We did not observe an inter-
action effect of sex x ACE I/D polymorphism on the 
phenotypes (all P > 0.2); therefore, all the analyses were 
performed with men and women together and sex was 
included as an additional covariate to the model. 
We also analysed the combined effect of ACE I/D and 
ACTN3 R577X polymorphisms on the study phenotypes by 
ANCOVA using two genotype combinations, i.e. ACE DD 
and ACTN3 RR + RX (which, at least hypothetically, 
might be more suitable for power/hypertrophy-oriented 
exercise tasks) versus ACE II + ID and ACTN3 XX group 
(Gomez-Gallego et al. 2009). We also compared the ACE 
DD and ACTN3 RR + RX group against the rest of study 
participants by ANCOVA. 
Finally, in order to examine whether the subjects with 
the best performance had also the 'best' genotype profile 
(i.e. ACE DD and ACTN3 RR + RX), we classified the 
population into two groups based on an arbitrary cut-off 
point: >90th of the sex-specific percentile and <90th of the 
sex-specific percentile. The rationale for choosing 90th 
percentile was based on the fact that subjects in the top 
10% might have a favourable genetic endowment to per-
form better. We performed logistic regression analysis to 
examine the association between the ACE DD and ACTN3 
RR + RX genotype combination and performance (>90th 
of the sex-specific percentile) after adjusting for sex, age, 
weight and height. To further investigate the influence of 
the 90th percentile cut-off on the findings, we performed 
sensitivity analyses after varying these cut-offs (>75th and 
>95th). 
All statistical analyses were performed using the PASW. 
We used the Bonferroni and Holm method to correct for 
multiple testing (Holm 1979; Shaffer 1995). This method 
proceeds as follows: Sort the P values of the k tests in 
increasing order, i.e., Pu P2,..., i\,..., ¿V If Pi > a/k, none 
of the k tests are significant, and the test procedure is fin-
ished. If Pi < aJk, test 1 is significant, and now P2 is 
examined. If P2 > aJ(k — 1), none of the (k — 1) remain-
ing tests are significant, but if P2 < aJ(k — 1), test 2 is 
significant and P3 is examined. This procedure goes on 
until Pt > ul{k - i + 1). 
Results 
ACE I/D genotype distributions met Hardy-Weinberg 
equilibrium (j — 0.050, P — 0.821). We did not observe 
differences (j — 2.225, P — 0.329) in the genotype dis-
tributions in men [30 (13.9%), 103 (47.7%) and 81 (37.5%) 
for II, ID and DD, respectively] and women [9 (13.4%), 26 
(38.8%) and 32 (47.8%) for II, ID and DD, respectively]. 
The genotype distribution of the ACTN3 R577X poly-
morphism also respected the Hardy-Weinberg equilibrium 
and did not differ by sex (Santiago et al. 2009). 
The association between the ACE I/D polymorphism 
and study phenotypes is presented in Table 1. We did not 
observe any significant effect of the polymorphism on 
study phenotypes, although a 'minor trend' (P — 0.063 and 
P — 0.062) was found for the SJ tests. We repeated the 
analyses separately in men and women and the results did 
not materially change (data not shown). Likewise, the 
mean estimates of the study phenotypes were similar in the 
ACE II + ID and ACTN3 XX and ACE DD and ACTN3 
RR + RX groups (Table 2). We performed separate anal-
yses comparing the ACE DD and ACTN3 RR + RX group 
versus the rest of subjects and the results remained the 
same (data not shown). The observed power ranged 
between 0.78 and 0.85. 
We found no association between the ACE DD and 
ACTN3 RR + RX genotype combination and performance 
(>90th of the sex-specific percentile) (Fig. 2). The results 
remained the same after changing the cut-off point to 
>75th percentile or to >95th percentile, or after repeating 
the analysis by sex (data not shown). 
Discussion 
Our data suggest that the ACE I/D polymorphism, indi-
vidually or in combination with the ACTN3 R577X poly-
morphism, does not have a major influence on explosive 
muscle power in young, non-athletic adults, at least with 
the multi-joint exercise tests we used (see below). We only 
found a 'minor trend' for an influence of the ACE I/D 
polymorphism on squat jump tests (P values of 0.063 and 
0.062 for the dominant model in flight time and vertical 
Table 1 Mean estimates of study phenotypes by genotypes of ACE I/D (rs 1799752) polymorphism 
Vertical jump tests 
SJ 
Flight time (s) 
Vertical displacement of CG (cm) 
CMJ 
Flight time (s) 
Vertical displacement of CG (cm) 
Sprint tests 
30 m running start 
Time at 15 m (s) (A) 
Time at 30 m (s) (B) 
30 m standing start 
Time at 15 m (s) (C) 
Time at 30 m (s) (D) 
Acceleration index 
C - A (s) 
D - B (s) 
II (B = 
Mean 
556.1 
38.2 
564.6 
39.4 
1.99 
3.89 
2.58 
4.53 
0.59 
0.65 
39) 
SEM 
6.3 
0.9 
6.6 
0.9 
0.02 
0.04 
0.02 
0.04 
0.02 
0.03 
ID (B = 
Mean 
541.1 
36.2 
552.8 
37.7 
2.00 
3.91 
2.61 
4.56 
0.61 
0.65 
129) 
SEM 
3.5 
0.5 
3.7 
0.5 
0.01 
0.02 
0.01 
0.02 
0.01 
0.02 
DD (B = 
Mean 
545.9 
36.9 
556.5 
38.3 
1.99 
3.91 
2.61 
4.56 
0.62 
0.65 
113) 
SEM 
3.8 
0.5 
4.0 
0.5 
0.01 
0.02 
0.01 
0.02 
0.01 
0.02 
Padd 
0.432 
0.451 
0.546 
0.609 
0.801 
0.727 
0.439 
0.686 
0.332 
0.944 
P recess 
0.819 
0.773 
0.863 
0.771 
0.566 
0.972 
0.821 
0.924 
0.455 
0.941 
P dom 
0.063 
0.062 
0.155 
0.160 
0.765 
0.525 
0.229 
0.510 
0.385 
0.972 
Analyses adjusted for sex, age, weight and height. P values before applying correction for multiple testing 
recess recessive (DD + ID vs. II), dom dominant (II + ID vs. DD), SJ squat jump, CMJ counter-movement jump, CG centre of gravity, SEM 
standard error of the mean 
Table 2 Estimates of study 
phenotypes in the ACE II + ID 
and ACTN3 XX and ACE DD 
and ACTN3 RR + RX groups 
SJ squat jump, CMJ counter-
movement jump, CG centre of 
gravity, SEM standard error of 
the mean 
* Analyses adjusted for sex, 
age, weight and height; P values 
before applying correction for 
multiple testing 
Vertical jump tests 
SJ 
Flight time (s) 
Vertical displacement 
CMJ 
Flight time (s) 
Vertical displacement 
Sprint tests 
30 m running start 
Time at 15 m (s) (A) 
Time at 30 m (s) (B) 
30 m standing start 
Time at 15 m (s) (C) 
Time at 30 m (s) (D) 
Acceleration index 
C - A (s) 
D - B (s) 
of CG (cm) 
of CG (cm) 
ACE II + ID and ACTN3 
XX (B = 
Mean 
538.3 
35.8 
549.6 
37.3 
2.0 
4.0 
2.6 
4.6 
0.6 
0.7 
= 36) 
SEM 
7.1 
1.0 
7.3 
1.0 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
ACE DD and ACTN3 
RR + RX (B 
Mean 
548.3 
37.2 
558.2 
38.5 
2.0 
3.9 
2.6 
4.6 
0.6 
0.7 
: = 97) 
SEM 
4.4 
0.6 
4.5 
0.6 
0.0 
0.0 
0.0 
0.0 
0.0 
0.0 
p* 
0.383 
0.373 
0.641 
0.636 
0.612 
0.420 
0.152 
0.109 
0.340 
0.626 
4H 
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Fig. 2 Association between the AC£ DD and ACTN3 RR + RX 
genotype combination and performance (>90th of the sex-specific 
percentile). Values are odds ratio and 95% confidence intervals 
displacement of centre of gravity, respectively). Thus, with 
the present design for phenotype assessment, the hypoth-
esis that ACE I/D and ACTN3 R557X genotypes might 
exert a combined influence on leg muscle phenotypes was 
not corroborated. 
Though controversy exists (McCauley et al. 2009, 2010; 
Moran et al. 2006), the ACE D allele has been associated 
with power-related phenotypes in non-athletic populations 
(Giaccaglia et al. 2008; Hopkinson et al. 2004; Yamin et al. 
2007); this allele has also been associated with elite 
"sprint" athletic performance (Myerson et al. 1999; Woods 
et al. 2001), though more recent data do not corroborate 
such association (Amir et al. 2007; Scott et al. 2005, 2010). 
However, the association between leg 'explosive' muscle 
power and the ACE I/D polymorphism had not been 
studied to date. 
We assessed 'explosive' muscle power using jumping 
and sprinting testing tests in young, non-athletic adults. 
Jumping and sprinting are naturally occurring multi-joint 
movements in humans that involve the coordinated par-
ticipation of the majority of lower limb muscles (Ashley 
and Weiss 1994; Brown and Weir 2001). On one hand, we 
believe that the tests we used for muscle phenotype 
assessment represent both a novelty and a strength of our 
study versus previous reports in the field that used other 
tests for muscle power assessment, e.g. isokinetic tests 
involving single-joint movements (e.g. knee-extension) at 
relatively low angular velocities (<240° s_1) (McCauley 
et al. 2009, 2010). Indeed, during actual, natural high 
muscle power actions (e.g. sprint and jumps), angular 
velocities at the hip or knee joints can approach 800°-
1,000° s"1 (Bosco et al. 1983). The fact that we only used 
multi-joint tests can also be viewed as a limitation of our 
study because other factors aside from the skeletal muscle 
tissue per se (see below) could have influenced the results 
of our tests and masked any potential genotype effect. This 
is particularly true for sprinting. In this type of exercise 
task, owing to the short duration of the foot contact on the 
ground, the rate of force development (RFD) is the critical 
performance determinant. The RFD is, in turn, influenced 
by several factors such as muscle fibre type, synchroniza-
tion of motor units, tendon stiffness, or lean mass of lower 
extremities (Perez-Gomez et al. 2008). In contrast, the 
ability of leg muscles (quadriceps) to produce power dur-
ing the concentric phase of muscle contraction is the crit-
ical factor affecting stationary vertical jumps as the ones 
we used here (Ham et al. 2007). Future research in the field 
is necessary combining both single and multi-joint exercise 
tasks. 
Scarce data are available on the combined influence of 
ACE I/D and ACTN3 R577X polymorphisms on muscle 
power phenotypes. In elite athletes, data are rather contro-
versial. We showed no significant combined influence of 
ACTN3 R577X and ACE I/D variations on the peak muscle 
power output generated by elite endurance athletes during 
cycle-ergometer testing until exhaustion (Gomez-Gallego 
et al. 2009). No differences were found in peak power 
output between those cyclists with the ACE DD and ACTN3 
RR + RX and ACE II + ID and ACTN3 XX genotype 
combinations. More recently, Eynon et al. (2009) reported 
an association between the combination of both ACE and 
ACTN3 polymorphisms and elite sprint athletic status 
(Eynon et al. 2009), yet they found that the most 'favour-
able' allele combination for a sprinter was the ACTN3 R 
allele (i.e., theoretically power oriented) + the ACE I allele 
[i.e. theoretically more endurance oriented according to 
other studies (Jones et al. 2002; Williams et al. 2000)]. With 
regard to this, in our study, we found no significant asso-
ciation between the ACTN3 R allele + ACE I allele com-
bination (data not shown). As for non-athletic populations, 
our findings concur with recent data on elderly people 
showing no association (individually or combined) between 
power muscle phenotypes and ACE I/D + ACTN3 R577X 
genotype combinations (Bustamante-Ara et al. 2010). 
Besides the aforementioned lack of data on single-joint 
tests for muscle power assessment, our study has other 
potential limitations. We did not measure the activity of the 
ACE gene product (i.e. ACE) or circulating levels of the 
muscle growth factor angiotensin II. With regard to this, 
although serum ACE activity was suggested to be signifi-
cantly dependent on ACE genotypes in young Caucasian 
adults (with the highest enzymatic levels been found in the 
DD genotype), it does not seem to influence their muscle 
functional or contractile properties (McCauley et al. 2009). 
Further research is also necessary to assess the combined 
influence of other candidate genes with a potential effect on 
muscle phenotypes, e.g. the myostatin gene. 
In summary, though the ACE I/D polymorphism is a 
strong candidate to modulate some exercise-related phe-
notypes or athletic performance status, this polymorphism, 
alone or in combination with the ACTN3 R577X variation, 
does not seem to exert a major influence in the muscle 
'explosive' power of non-athletic young healthy adults. 
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